NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Learn more

Workspace · Cancer algorithms · Leukemia

Leukemia

Leukemia · 67,790 new · 23,910 deaths (ACS 2026) · mortality 5.7 per 100k · 5-yr RS 68.6% (SEER)

Mortality 5.7 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 1.6% (SEER Stat Facts). 563,581 people living with leukemia in 2023. Separate from the NHL heme stub. No invented incidence formula.

563,581 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 68 · at death 76 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 18.5 / women 11.5 per 100k · mortality men 7.6 / women 4.3 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases stable (2014–2023). Death rates falling 1.8% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic White men 20.6 per 100k. Highest death rate: Non-Hispanic White men 8.2 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
GroupInc. menInc. womenDeaths menDeaths women
Hispanic14.210.15.13.3
Non-Hispanic American Indian/Alaska Native15.110.55.83.7
Non-Hispanic Asian/Pacific Islander10.46.74.02.4
Non-Hispanic Black14.09.76.44.0
Non-Hispanic White20.612.58.24.6

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2025 · People without ALL symptoms · ACS ALL type page (2025): there are no special tests recommended to detect ALL early. This is not a pan-leukemia screen and not a staging engine. Official copy: there is no standard staging system for leukemia.

Cited ACS statement only. Not a screening engine. ACS-all-detect

ACS early-detection pointer

ACS 2025 · People without CML symptoms · ACS CML type page (2025): there are no widely recommended screening tests for chronic myeloid leukemia. This is not a pan-leukemia screen and not a staging engine. Official copy: there is no standard staging system for leukemia.

Cited ACS statement only. Not a screening engine. ACS-cml-detect

ACS early-detection pointer

ACS 2025 · People without AML symptoms · ACS AML type page (2025): no screening tests have been shown to be helpful in finding AML early. This is not a pan-leukemia screen and not a staging engine. Official copy: there is no standard staging system for leukemia.

Cited ACS statement only. Not a screening engine. ACS-aml-detect

ACS early-detection pointer

ACS 2025 · People without CLL symptoms · ACS CLL type page (2025): there are no widely recommended screening tests for chronic lymphocytic leukemia. CLL is often found on a blood test done for another reason; that is not a CBC screening engine. This is not a pan-leukemia screen and not a staging engine. Official copy: there is no standard staging system for leukemia.

Cited ACS statement only. Not a screening engine. ACS-cll-detect

Surveillance pointer

ACS-all-follow 2025 · cited only · ACS ALL living-as-a-survivor page names frequent follow-up exams and tests for at least several years after treatment. Those months are not encoded. Official copy: there is no standard staging system for leukemia. Not a pan-leukemia or MRD engine.

Named public source only. Not a personal follow-up calendar. ACS-all-follow

Surveillance pointer

ACS-cml-follow 2025 · cited only · ACS CML living-as-a-survivor page names close follow-up during and possibly after treatment, with exams and lab tests to see how treatment is working. Those months are not encoded. Complementary to the ALL living-as pointer. Official copy: there is no standard staging system for leukemia. Not a BCR-ABL or TKI monitoring engine.

Named public source only. Not a personal follow-up calendar. ACS-cml-follow

Surveillance pointer

ACS-aml-follow 2025 · cited only · ACS AML living-as-a-survivor page names frequent follow-up exams, probably every month or so at first and then less often, for at least several years. Those months are not encoded. Complementary to the ALL living-as pointer. Official copy: there is no standard staging system for leukemia. Not a pan-leukemia or MRD engine.

Named public source only. Not a personal follow-up calendar. ACS-aml-follow

Surveillance pointer

ACS-cll-follow 2025 · cited only · ACS CLL living-as-a-survivor page names close follow-up before, during, and after treatment, with exams and lab tests for side effects or signs of CLL. Those months are not encoded. Complementary to the ALL living-as pointer. Official copy: there is no standard staging system for leukemia. Not a CBC surveillance engine.

Named public source only. Not a personal follow-up calendar. ACS-cll-follow

Surveillance pointer

ACS-cll-follow 2025 · cited only · ACS CLL living-as page names later cancers after CLL, including skin cancers. Those named later cancers are not encoded. Complementary to the CLL living-as row. The CLL type page is not a pan-leukemia screen. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-cll-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names cancer-related fatigue, cognitive impairment after chemo, peripheral neuropathy, and later heart problems after anthracyclines. Those names are not encoded. Complementary to the ALL living-as pointer. Official copy: there is no standard staging system for leukemia. Not a BCR-ABL, MRD, or pan-leukemia engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names echoes after cardiotoxic chemo and lung function tests after some chemo or a stem-cell or bone-marrow transplant, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the ALL living-as and late-effects pointers. Official copy: there is no standard staging system for leukemia. Not a BCR-ABL, MRD, or pan-leukemia engine. No invented printout field.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Official copy: there is no standard staging system for leukemia.

Toxicity pointer

ACS-all-follow 2025 · empty on purpose · ACS ALL living-as-a-survivor page names treatment side effects that may last. Those late effects are not encoded. Official copy: there is no standard staging system for leukemia. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-all-follow

Toxicity pointer

ACS-cml-follow 2025 · empty on purpose · ACS CML living-as-a-survivor page names treatment side effects that may last the rest of your life. Those late effects are not encoded. Official copy: there is no standard staging system for leukemia. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-cml-follow

Toxicity pointer

ACS-aml-follow 2025 · empty on purpose · ACS AML living-as-a-survivor page names possible side effects of certain treatments. Those late effects are not encoded. Official copy: there is no standard staging system for leukemia. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-aml-follow

Toxicity pointer

ACS-cll-follow 2025 · empty on purpose · ACS CLL living-as-a-survivor page names treatment side effects that may last the rest of your life. Those late effects are not encoded. Official copy: there is no standard staging system for leukemia. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-cll-follow

Toxicity pointer

ACS-cll-follow 2025 · empty on purpose · ACS CLL living-as page names later cancers after CLL. Those second-cancer risks are not encoded. Complementary to the CLL living-as row. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-cll-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later fatigue, cognitive impairment, neuropathy, and heart problems after anthracyclines. Those late effects are not encoded. Official copy: there is no standard staging system for leukemia. Complementary to the ALL living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names echoes after cardiotoxic chemo and lung function tests after some chemo or transplant. Those named tests are not encoded. Official copy: there is no standard staging system for leukemia. Complementary to the ALL living-as pointer. No invented printout field. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Official copy: there is no standard staging system for leukemia.

Late toxicity printout

No invented printout field. Complementary ACS follow-up-care and late-effects pointers stay on this page.

Kidney, thyroid, and leukemia stay unmapped. Cadences are not encoded.

Official copy: there is no standard staging system for leukemia.

All printouts →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-leukemia · stub · none · v2-stub-leukemia

Stage table is not encoded for this stub. All-stage 5-year RS is 68.6% (SEER common sites).

Percent of cases by stage

There is no standard staging system for leukemia.

  • lifetime

    Leukemia birth-to-death

    ≈ 1.6%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    No USPSTF leukemia screening rec cited

    ACS ALL, CML, AML, and CLL type pages: no special ALL test, no widely recommended CML or CLL screen, and no AML screen shown to help find AML early. Official copy: there is no standard staging system for leukemia. Do not invent localized / regional / distant.

    not encoded

  • surveillance

    ACS follow-up cited — ALL months not encoded

    Cited ACS ALL living-as-a-survivor page, plus complementary CML, AML, and CLL living-as pages. Not a pan-leukemia or MRD engine.

    not encoded

  • toxicity

    ACS late effects cited — ALL months not encoded

    Empty on purpose. Official copy: there is no standard staging system for leukemia.

    not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    No USPSTF leukemia screening rec cited

    ACS ALL, CML, AML, and CLL type pages: no special ALL test, no widely recommended CML or CLL screen, and no AML screen shown to help find AML early. Official copy: there is no standard staging system for leukemia. Do not invent localized / regional / distant.

    not encoded

  • surveillance

    ACS follow-up cited — ALL months not encoded

    Cited ACS ALL living-as-a-survivor page, plus complementary CML, AML, and CLL living-as pages. Not a pan-leukemia or MRD engine.

    not encoded

  • toxicity

    ACS late effects cited — ALL months not encoded

    Empty on purpose. Official copy: there is no standard staging system for leukemia.

    not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    No USPSTF leukemia screening rec cited

    ACS ALL, CML, AML, and CLL type pages: no special ALL test, no widely recommended CML or CLL screen, and no AML screen shown to help find AML early. Official copy: there is no standard staging system for leukemia. Do not invent localized / regional / distant.

    not encoded

  • surveillance

    ACS follow-up cited — ALL months not encoded

    Cited ACS ALL living-as-a-survivor page, plus complementary CML, AML, and CLL living-as pages. Not a pan-leukemia or MRD engine.

    not encoded

  • toxicity

    ACS late effects cited — ALL months not encoded

    Empty on purpose. Official copy: there is no standard staging system for leukemia.

    not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

  • screening

    No USPSTF leukemia screening rec cited

    ACS ALL, CML, AML, and CLL type pages: no special ALL test, no widely recommended CML or CLL screen, and no AML screen shown to help find AML early. Official copy: there is no standard staging system for leukemia. Do not invent localized / regional / distant.

    not encoded

  • surveillance

    ACS follow-up cited — ALL months not encoded

    Cited ACS ALL living-as-a-survivor page, plus complementary CML, AML, and CLL living-as pages. Not a pan-leukemia or MRD engine.

    not encoded

  • toxicity

    ACS late effects cited — ALL months not encoded

    Empty on purpose. Official copy: there is no standard staging system for leukemia.

    not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →